A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Oncologia Medica Genitourinaria
Drug: MK-3120 + pembro
Pathologies: Urological cancers (kidney, bladder, urinary tract, others)
The total number of investigational treatment arms will depend on the number of investigational agents evaluated. This study protocol will include a minimum of 1 investigational treatment arms. Refer to Appendix 6, Section 10.6.1. Arm A includes participants treated with MK-2140 and Arm B includes participants treated with MK-3120 plus pembrolizumab.
Last update: 17/04/2026